Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) presented additional PRIME study data showing that a single dose of Gemini durably normalized cellular inflammation and restored immunocompetence in stage 3–4 CKD patient samples.
Key findings: >85% had elevated cytokines predose, >60% had IL-1b/IL-6 elevations, and Gemini reduced elevated cytokines and restored LPS responsiveness through 7 days post‑dose.
Positive
- >85% of patients had elevated cytokines predose
- >60% had elevated IL‑1b and IL‑6 predose
- Single Gemini dose normalized inflammation through 7 days
- Gemini restored LPS responsiveness in immunoparalyzed patients
Negative
- None.
News Market Reaction – REVB
On the day this news was published, REVB gained 5.31%, reflecting a notable positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $229K to the company's valuation, bringing the market cap to $4.54M at that time. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
REVB was flat pre-announcement, while several biotech peers in screening (e.g., ELAB, SPRC, XRTX, SLXN) showed upside momentum, suggesting today’s clinical update is more stock-specific than part of a unified sector move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | GMP manufacturing | Positive | -1.1% | Initiation of GMP manufacturing for Gemini and placebo for later-stage trials. |
| Nov 20 | End-of-Phase 1 prep | Positive | -0.5% | FDA acceptance of end-of-phase 1 package and PRIME safety/efficacy data update. |
| Sep 10 | Top-line data webcast | Positive | +6.0% | Announcement of special webcast reviewing positive PRIME clinical results for Gemini. |
| Sep 09 | Top-line PRIME results | Positive | -17.4% | Groundbreaking top-line PRIME data showing inflammation normalization and safety. |
| Feb 26 | First patient dosed | Positive | -4.9% | Initiation of dosing in PRIME Phase 1b Gemini study in CKD patients. |
Clinical milestones for Gemini have frequently been followed by negative next‑day moves despite constructive trial updates, with only one of five recent clinical trial headlines producing a positive reaction.
Over the past year, Revelation has steadily advanced Gemini through its PRIME Phase 1b study in CKD, from first dosing in Feb 2025 to top‑line data in Sep 2025 and subsequent GMP manufacturing initiation in Jan 2026. These updates highlighted safety, inflammation normalization and immunocompetence restoration, plus FDA engagement on the AKI pathway. Yet four of five tagged clinical trial releases saw negative 24‑hour price reactions, suggesting a pattern of selling into positive Gemini‑related news that frames today’s additional PRIME data.
Historical Comparison
Past Gemini clinical-trial headlines moved the stock an average of -3.56% over 24 hours. Today’s PRIME data release, with a pre-news move of 0%, fits within a generally muted-to-negative historical reaction profile.
Clinical-trial news shows a progression from first dosing in PRIME, to positive Phase 1b top-line data, to GMP manufacturing readiness, supporting advancement of Gemini toward pivotal AKI studies.
Regulatory & Risk Context
An amended Form S-3/A shelf filed on 2025-09-29 registers shares underlying Class I warrants exercisable at $2.20 per share. If fully exercised for cash, the company could receive up to $28,743,000. The shelf is effective with at least one usage via a 424B3 filed on 2026-02-11, indicating an established framework to tap warrant-related capital.
Market Pulse Summary
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with the clearly favorable PRIME data showing Gemini normalizing cellular inflammation and restoring immunocompetence for up to 7 days after a single dose. Historically, Gemini trial news averaged a -3.56% move with mixed reactions, so a large gain would mark a break from prior selling into strength. Investors would need to weigh this against the existing capital structure, including warrant-driven funding capacity of up to $28,743,000 under the active shelf.
Key Terms
chronic kidney disease medical
acute kidney injury medical
peripheral blood mononuclear cells medical
toll-like receptor 4 agonist medical
cytokine medical
AI-generated analysis. Not financial advice.
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose -
-Gemini durably normalizes cellular inflammation and restores immunocompetence -
SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease (CKD) patients peripheral blood mononuclear cells. Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide, a toll-like receptor 4 agonist, in development for the treatment of acute and chronic inflammation-driven diseases such as acute kidney injury (AKI) and CKD.
In the PRIME study, a majority of patients (>
Acute and chronic inflammatory disease is driven by increased cytokine production, as a result of activation of innate immune cells. This dysregulation in cellular activity contributes to perpetuation and progression of disease. Data from the PRIME clinical study demonstrate that treatment with a single dose of Gemini can durably normalize inflammation at the cellular level, and restored immunocompetence.
"We are pleased to have had the opportunity to share our compelling clinical data for the treatment of inflammatory disease in this forum," said James Rolke, Chief Executive Officer of Revelation. "This engagement with key opinion leaders and health care providers treating AKI is another step in our effort to initiate our planned pivotal clinical study in AKI later this year."
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI program) and Revelation intends to initiate a pivotal Phase 2/3 clinical study in AKI later this year. In addition to AKI, Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD program). Due to its unique biology, Gemini has the potential to be a treatment for any disease associated with dysregulated inflammation. The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two phase 1 clinical studies. See additional detail here.
About AKI
Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease, and death.
AKI is a major cause of morbidity and mortality, affecting more than
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on innovative solutions for acute and chronic disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of acute kidney injury and chronic kidney disease. Gemini has the potential to treat any acute or chronic condition driven by dysregulated inflammation.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Revelation Biosciences (REVB) announce about the PRIME study on March 30, 2026?
How common were elevated cytokines in PRIME study patients according to REVB?
What immune effect did a single Gemini dose produce in the PRIME study (REVB)?
Does the PRIME data suggest Gemini could treat inflammation-driven kidney disease (REVB)?
Will REVB start a pivotal AKI trial after PRIME results in 2026?
